| Company | Value | Change | %Change |
|---|
About Anlon Healthcare IPO
The proposed IPO would consist solely of a fresh issue of 1.4 crore equity shares, with no offer-for-sale component.
The company plans to use the proceeds from the IPO for various purposes: ₹30.7 crore will be allocated for expanding its manufacturing facility, ₹5 crore for debt repayment, and ₹35.98 crore for working capital needs. The remaining funds will be used for potential acquisitions and general corporate expenses.
Anlon Healthcare, based in Gujarat, operates a single manufacturing facility and four R&D labs. The company is led by promoters Punitkumar Rasadia and Meet Atulkumar Vachhani, who together hold a 70.26% stake, while the remaining 29.74% is owned by public shareholders.
The company manufactures advanced pharmaceutical intermediates which serve as raw material in the manufacturing of active pharmaceutical ingredients. The company also manufactures APIs which serve as a raw material for pharmaceutical formulations in preparation of various types of finished dosage formula, such as tablets, capsules, ointment, syrup ingredients in nutraceuticals formulations, personal care products, and animal health products.
Also Read : TCS partners with Switzerland’s Landis+Gyr to help utilities meet carbon emission goals
